Targeting Epidermal Growth Factor Receptor in Triple Negative Breast Cancer: New Discoveries and Practical Insights for Drug Development

Breast cancer is among the most frequent tumors worldwide and over 200,000 women will develop the disease in the United States in 2016 [1]. Breast cancer is a heterogeneous disease, clinically classified based on the presence of hormonal receptors for estrogen (ER) and progesterone (PR), and the expression/amplification status of the human epidermal growth factor receptor 2 (HER2) protein/oncogene [2].

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2jgHpBS
via IFTTT